Why Rare Disease Marketing Requires More Than a Traditional HCP List

Each rare disease, by definition, affects relatively few people. Taken together, they affect an enormous number. Orphanet, one of the most widely used rare disease information resources and a reference for bodies such as the WHO and the EU, counts more than 6,500 known rare diseases, affecting an estimated 329 to 624 million people worldwide. For pharmaceutical and biotech companies, that combination of small individual populations and huge collective need is exactly what makes rare disease marketing so different.

Rare diseases include a wide range of genetic disorders, malformations, syndromes and other conditions. Patients are few for any single disease and often spread across wide geographic areas. Orphan drugs serve these small, scattered populations, which makes commercialization genuinely hard. A therapy might be relevant to a few thousand patients nationally, treated by a few hundred physicians, many of whom don't yet know the therapy exists.

That's why the usual approach of buying a large HCP list by specialty and running broad campaigns rarely works here. To succeed, pharma teams need to pinpoint the specific patients, specialists and organizations that matter across a fragmented landscape. For rare disease marketers, the challenge isn't finding more healthcare professionals. It's finding the right ones.

Why a specialty list doesn't reflect the rare disease patient population

A traditional HCP list starts with specialty: all neurologists, all hematologists, all endocrinologists. But rare disease care usually spans several specialties, and within any one of them, only a small share of physicians will ever see a patient with a given condition.

An HCP may meet a rare disease patient at very different points: when symptoms first appear, during diagnostic workup, at referral, during treatment or in long-term care. Their relevance depends on where they sit in that journey, not just on the specialty attached to their name.

That creates two problems for marketers who rely only on specialty lists. First, they reach many physicians with the right credentials but little connection to the disease, which wastes budget and trains busy clinicians to ignore future messages. Second, they miss physicians outside the obvious specialty who play an important role in recognizing or referring patients.

For rare disease outreach, specialty should be a starting point, not the final targeting criterion. A stronger audience considers each HCP's role, relevance and connection to the wider care pathway.

The patient journey matters more than the HCP title

Rare disease patients often see many clinicians before getting an accurate diagnosis, a pattern widely known as the "diagnostic odyssey." In a 2024 EURORDIS Rare Barometer survey, the average time to diagnosis was 4.7 years, and 25% of patients needed eight or more consultations before their diagnosis was confirmed.

That journey typically runs through primary care physicians, general specialists, diagnostic services and eventually specialist or reference centers. Along the way, a lot of people touch the patient's care, and many of them have real influence over how quickly the patient reaches the right treatment.

For marketers, a few practical points follow:

• The most relevant HCP isn't always the obvious specialist. The physician who notices an unusual pattern of symptoms can matter as much as the one who confirms the diagnosis.
• Different stages need different messages. Recognition and referral criteria for primary care and general specialists; diagnostic pathways for specialists; treatment and access information for treating physicians and centers.
• Role in the care journey matters as much as title. Mapping who influences diagnosis, referral, treatment and ongoing care gives you a far more useful audience than a specialty filter alone.

Referral networks reveal what traditional HCP lists miss

Diagnosing a rare disease usually takes coordination across specialties, because no single physician sees the full picture. A physician who never treats the condition may still play a critical part by recognizing early signs and sending the patient to the right specialist.

That makes referral patterns one of the most valuable inputs for building a rare disease audience. They show how patients move between primary care physicians, specialists, diagnostic centers and rare disease treatment centers, and which physicians sit at the crossroads.

The distinction matters when planning a campaign. A traditional list identifies the specialists most likely to treat a condition. It doesn't show the physicians who influence how patients reach them. Mapping those referral connections adds context that specialty alone can't, and the goal shifts from "who treats this disease?" to "who shapes how patients with this disease get diagnosed, referred and treated?"

Other groups often belong in the picture too: genetic counselors, specialist nurses, patient navigators and the staff of centers of excellence. In many rare diseases, they're the people patients and families talk to most.

Target rare disease specialists by relevance, not volume

Rare disease campaigns don't succeed by reaching the largest possible list. They succeed by reaching the right one. A smaller, disease-relevant audience will consistently outperform a broad, generic one, both in engagement and in how clinicians perceive your brand.

Effective segmentation starts broad and narrows with purpose. Begin with the therapeutic area, then refine by disease category, specialty, geography, organization and HCP role. Each layer sharpens the picture of which professionals intersect with the condition, rather than simply sitting nearby.

This is where healthcare data earns its keep. Not every physician in a specialty is equally relevant to a rare disease campaign, and the right data helps you organize HCPs and organizations around what matters: familiarity with the disease, relevant patient volume, institutional affiliation and clinical trial involvement.

A practical way to put this together:

1. Map the care pathway for the disease, from first symptoms to long-term management, and note which roles appear at each stage.
2. Identify the centers where patients are most often diagnosed and treated, such as academic medical centers, specialty clinics and designated centers of excellence.
3. Build the core audience of treating specialists at and around those centers.
4. Add the referral layer: the primary care physicians and general specialists who most often send patients there, with their own message about recognition and referral.
5. Include the wider care team, such as genetic counselors and specialist nurses, where they influence the patient journey.
6. Refresh regularly. Rare disease audiences are small, so a handful of physicians moving institutions can change your targeting significantly.

The objective was never list size. It's precision: an audience that mirrors the people and organizations shaping a rare disease's care pathway, aligned with what your campaign is trying to achieve.

Final thoughts

A traditional HCP list tells rare disease marketers who exists. A smarter audience strategy tells them who matters, why they matter and where they fit in the patient journey.

Rare diseases are often managed by a small, highly specialized group of physicians, frequently concentrated at academic medical centers, tertiary hospitals and specialty clinics, supported by a wider network of clinicians who recognize and refer patients. Reaching that group well isn't about casting a wider net. It's about casting a far more careful one.

MedicalProspects helps you identify the physicians and organizations who shape a rare disease's care pathway, so every piece of outreach reaches someone it's relevant to. If you're ready to build a relevance-first audience, get in touch with our team.

---